La-Radio 893

Healthcare Prof:

A receptor which is present within the nucleus of cells can, when activated, slow the growth of tamoxifen-resistant breast cancer cells, a new study located. The study built on the recent discovery that farnesoid X receptor (FXR) a nuclear receptor found mainly in the liver is discovered in breast cancer tissue. Although previous investigation showed that FXR can slow proliferation of breast cancer cells, it was not recognized whether it could do the same with tamoxifen-resistant cells.

The analysis is component of an effort to overcome tamoxifen resistance in breast cancer patients who are good candidates for tamoxifen remedy, but who either don’t respond towards the drug or who create resistance over time. These findings suggest that FXR, when activated by chenodeoxycholic acid (a bile acid) or GW4064 (a synthetic), can slow the proliferation of breast cancer cells that are tamoxifen resistant, said 1 of the study’s authors, Cinzia Giordano.

Giordano, Donatella Vizza, Salvatore Panza, Ines Barone, Daniela Bonofiglio, Suzanne A. Fuqua, Stefania Catalano and Sebastiano And????? carried out the study, “Activated farnesoid X receptor inhibits growth of tamoxifen resistant breast cancer cells.” The researchers are from the University of Calabria in Italy, except Dr Fuqua, who’s with Baylor College of Medicine in Houston.

The study will probably be presented in the Experimental Biology 2010 conference on Saturday, April 24 and again on Tuesday, April 27. The American Society for Investigative Pathology is sponsoring the sessions. The conference takes location in Anaheim April 24-28.

Maintaining tamoxifen sensitivity is key

Tamoxifen is an efficient breast cancer treatment for patients who are estrogen receptor positive the majority of breast cancer patients. Breast cancer cells, which require estrogen to grow, have estrogen receptors to permit them to take in estrogen. Tamoxifen interferes using the cancer cells’ ability to obtain estrogen and within the process inhibits the ability of the cancer cells to proliferate.

Tamoxifen generally works well on breast cancer cells that are estrogen receptor positive, but some cells which are receptor positive either don’t respond towards the drug, or they turn into resistant. When tamoxifen is unable to inhibit breast cancer cell growth in estrogen-positive patients, it truly is called hormonal resistance.

Recent studies had already shown that FXR, frequently found in the liver, induces death in breast cancer cells. The researchers wanted to find out if FXR, when activated in breast cancer tissue, would manage the growth of tamoxifen-resistant cells. They used two types of receptor-positive breast cancer cells:

1. MCF-7, which is sensitive to tamoxifen; that is, tamoxifen keeps these cancer cells in check

two. MCF-7TR, which is resistant to tamoxifen; which is, the drug does not keep the cancer in check.

The investigation team activated FXR with either a bile acid, chenodeoxycholic acid, or perhaps a synthetic, GW4064. Once FXR was activated, the researchers located that it reduced the survivability of both the tamoxifen-sensitive and tamoxifen-resistant cells. In reality, FXR inhibited the tamoxifen-resistant cancer cells (MCF-7TR) more than the tamoxifen sensitive cells.

How does it work?

The researchers found that FXR inhibited expression of a growth factor signaling mediator — human epidermal growth factor receptor 2 (HER2). HER2 is present in 20% of breast cancers and is associated with enhanced malignancy and poorer prognosis. The over-expression of HER2 on the breast cancer cell surface is believed to disrupt the cell’s ability to control growth, Giordano stated, permitting the cells to rapidly proliferate. FXR appears to inhibit that process.

Why would FXR work greater against MCF-7TR, the tamoxifen-resistant cells? Part of the explanation might be that MCF-7TR relies a lot more on HER2, and FXR targets HER2, Giordano stated. That would make the tamoxifen-resistant cancer cells a lot more vulnerable to activated FXR, she stated.

“This is an ‘in vitro’ preclinical study, but of course the next step will be to test this in vivo making use of mice implanted with tamoxifen-resistant breast cancer cells,” said Giordano.

The American Society for Investigative Pathology (ASIP) can be a society of biomedical scientists who investigate mechanisms of illness. Investigative pathology is an integrative discipline that links the presentation of illness within the whole organism to its fundamental cellular and molecular mechanisms. It uses a variety of structural, functional, and genetic techniques and ultimately applies research findings to the diagnosis and treatment of diseases. ASIP advocates for the practice of investigative pathology and fosters the professional career development and education of its members.

Source: Federation of American Societies for Experimental Biology (FASEB)

five (4 votes)

Healthcare Prof:

4 (1 votes)

Usually when all else fails with a technical device, a “reset” button may be pressed, preventing a glitch from going any further. What if that could be done with threats to a person’s well being? Investigators from The Cancer Institute of New Jersey (CINJ) as well as the Environmental & Occupational Wellness Sciences Institute (EOHSI) which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, have found that a type of a dietary trace element identified as selenium can support reset a cell’s “biological clock” when it is disrupted by a chemical cancer-causing agent (carcinogen). The findings ultimately might aid prevent the development of breast cancer. CINJ can be a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

Studies have shown that one’s “biological clock” (circadian rhythm) – responsible for regulating such functions as blood pressure, appetite, immune function and far more – plays a critical role inside the growth of cells and how those cells react to environmental and internal stressors. A person’s normal circadian rhythm might be interrupted by genetic manipulation, exposure to chemical carcinogens, and exposure to light at night for folks who do shift work. Such interruption, the researchers say, could negatively impact how cells respond to and repair DNA damage. Epidemiological studies have repeatedly shown that operating the night shift, for instance, is linked to an increased threat of endometriosis, breast cancer in females, and prostate cancer in men, prompting the International Agency for Cancer Study to classify shift work as a probable human carcinogen.

Separate studies have shown that the organic type of selenium recognized as methylselenocysteine (MSC), produced by plants, exhibits chemopreventive effects inside the early stages of tumor development by slowing growth when exposed to a chemical carcinogen. Other studies done previously by CINJ’s Associate Director for Public Well being Science, Helmut Zarbl, PhD, ATS, and colleagues, were the initial to suggest an association in between circadian rhythm and cancer prevention.

The team’s existing research, published in today’s online edition of Cancer Prevention Analysis extends those findings having a focus on nitrosomethylurea (NMU), a chemical carcinogen. Although human exposure to this agent is uncommon, as it’s not produced in mass quantities and is only employed inside the laboratory setting, exposure to other chemicals with the same mode of action (DNA alkylation) is not. In this most current study, the team demonstrated on experimental models that a single dose of NMU drastically disrupted circadian rhythm in mammary cells, indicating that loss of circadian rhythm from something other than shift work may possibly also contribute to cancer. Investigators also discovered that the biological clock was reset and restored when dietary MSC was given following exposure.

While all cells inside the body have a biological clock, these clocks all require to be synchronized in order to coordinate the body’s overall physiology. Synchronization typically occurs as a result of blood levels inside the hormone melatonin, whose levels are controlled by the amount of light entering the eyes. Melatonin synchronizes cellular clocks by binding to a specific receptor on the surface of all cells. This really is why folks frequently take melatonin to decrease the amount of time required to obtain over jet lag. Another study (Fang et. al.) showed that exposure to NMU prevented melatonin receptors from being produced in mammary (breast) cells, therefore creating them resistant to melatonin levels within the blood. Dietary MSC restores the normal rhythmic expression of the cell surface melatonin receptor, permitting melatonin to reestablish a normal biological clock.

How, then, does restoration of circadian rhythm prevent breast cancer development? According to the authors, it appears that the biological clock also regulates day-to-day changes in therelated genes and proteins that repair DNA harm induced by both environmental agents and those internal towards the body. By interrupting the production of these genes, chemical carcinogens and shift work affect normal control mechanisms and make cells much more vulnerable to mutations caused by DNA damage. By restoring normal circadian rhythm, MSC can reverse these effects, at least in experimental models, thus blocking estrogen-generated promotion of cancer development in breast tissue.

“These findings are substantial since they show how disruption of circadian rhythm can improve the danger of mammary cancer risk, and how a simple dietary supplement can reverse this effect, restore rhythm, and lessen cancer incidence, at least in experimental models. If MSC has the same effect in individuals, our outcomes could have considerable implications for alleviating the increased threat of breast and prostate cancers related to shift work,” noted Zarbl, who’s a professor of toxicology at UMDNJ-Robert Wood Johnson Medical School and the director of the National Institute of Environmental Wellness Sciences (NIEHS) Center for Environmental Exposures and Disease at EOHSI.

Zarbl and colleagues are nearing completion on the first phase of a related study whose focus is on hospital workers. The aim is to determine whether shift work also disrupts the cell’s response to estrogens and if this effect might be reversed by dietary MSC.

Along with Zarbl, the author team for the Cancer Prevention Research study consists of Ming Zhu Fang, PhD, EOHSI; and Xun Zhang, PhD, who was a graduate student at the University of Washington when the work was initiated in Dr. Zarbl’s lab, then in the Fred Hutchinson Cancer Research Center. The investigation was supported by National Institutes of Well being grants U19ES011387, P30ES005022, P30ES007033, and funds from EOHSI.

Source
Cancer Institute of New Jersey

five (1 votes)

Healthcare Prof:

5 (two votes)

The Wall Street Journal: “A prominent director at WellCare Well being Plans Inc. resigned Wednesday and raised questions about accounting practices in the Medicare and Medicaid company. Regina Herzlinger, the head of the board’s audit committee and a professor of business administration at Harvard Business School, said internal audits identified WellCare overbilled the Illinois Medicaid plan by $1 million in 2009 and potentially overcharged states for almost $500,000 worth of maternity care.” She also said the company “ran afoul of Georgia’s requirements that it account for each patient visit for which it paid providers, resulting in a $610,000 fine.” Herzlinger also stated “she had hoped to offer oversight, as chairwoman of the audit committee, but that the board didn’t renominate her for re-election at this year’s annual meeting of shareholders.” It’s her opinion that “the board forced her out for asking questions about accounting problems and corporate-governance practices.” But “WellCare said good corporate-governance practices require it to bring in new board members periodically to offer a fresh perspective” (Johnson and Lublin, 4/24).

CQ HealthBeat: “A new battle involving breast cancer broke out Friday right after Wellness and Human Services Secretary Kathleen Sebelius sent a letter to WellPoint executives urging that the well being insurance giant instantly end ‘the unconscionable practice of deliberately working to deny wellness insurance coverage to women diagnosed with breast cancer’ within the wake of news reports about rescissions at WellPoint.” WellPoint President and CEO Angela Braly “said in a lengthy reply Friday afternoon that both Sebelius’ letter as well as the news story on which it was based ‘grossly misrepresent’ WellPoint’s efforts to prevent, detect and treat breast cancer among policy holders. … Under the law (PL 111-148), later this year insurance companies will be banned from dropping coverage for folks who turn out to be sick, a practice called rescissions.” Reuters reported on Friday that the company “used a computer algorithm that immediately targeted for aggressive fraud investigations ladies who began treatment for breast cancer. The ladies held policies with subsidiaries of WellPoint. … In a Thursday response to the news story, WellPoint stated it really is ‘simply wrong’ that the company targets breast cancer victims and in fact has worked to encourage prevention and early detection” (Norman, 3/23).

This details was reprinted from kaiserhealthnews.org with type permission from the Henry J. Kaiser Loved ones Foundation. You are able to view the whole Kaiser Day-to-day Wellness Policy Report, search the archives and sign up for e-mail delivery at kaiserhealthnews.org.

? Henry J. Kaiser Loved ones Foundation. All rights reserved.

Healthcare Prof:

Hundreds of females from across the UK have joined over 20 celebrities to record a unique charity single in aid of Cancer Study UK’s Race for Life. The track, led by DJ and Singer Sonique, who herself is at present undergoing therapy for breast cancer, is actually a remake of Cyndi Lauper’s 1980s classic ‘Girls Just Wish to Have Fun’. The single, which is on sale, to mark the start of Race for Life the UK’s largest women-only fundraising series, is sold exclusively by official Race for Life partner Tesco and available to download on iTunes , with proceeds going directly to aid beat cancer.

Sonique, whose lines on the track see her returning towards the microphone for the first time since her diagnosis last June, is joined on the song by a host of female celebrities which includes Coronation Street’s Kym Marsh, actress Caroline Quentin, Big Brother star Nicola T and also the X-Factor’s Lucie Jones. The track also features a number of inspirational girls who’ve been personally affected by cancer, as well as the contributions of females from around the UK, captured by mobile producers who have been touring shopping centres.

Sonique said: ‘Girls Just Wish to Have Fun’ really embodies the spirit of Race for Life since, although there’s a serious message behind the activity, it really does feel like the ultimate girls’ day out. The truth that any woman, no matter how good their voice is, has been in a position to get involved is brilliant and really captures the essence of Race for Life. It’s not competitive and ladies of all ages, shapes and sizes can take portion. I’d urge each woman to sign up for an event this year!”

Denya Dessena, a breast cancer survivor aged 39 from Crawley who also recorded lines for the track, said: ” I loved each minute of my day inside the recording studio – if you’d have told me a few months ago that I was going to record a single with so a lot of famous singers, I’d have said you had been mad! It’s wonderful to come together with so a lot of various women to take portion in this, due to the fact cancer is something that doesn’t discriminate – it can affect girls from all walks of life, regardless of age, money or status. It is been wonderful fun recording the single and I would love for it to go to number 1 so that we can raise as a lot money as achievable for Cancer Study UK.”

Now in its 17th year, Race for Life could be the UK’s largest women-only fundraising series, with more than 230 events taking location this summer. Women from across the UK come together to simply walk, jog or run 5k and raise money to help beat cancer. Since Race for Life began in 1994, there has been a 15 per cent drop inside the death rate from cancer, something that money raised from Race for Life has helped to achieve. This year the charity is hoping over 700,000 women come together to raise an incredible ????60 million to fund Cancer Investigation UK’s life saving work.

Each Race for Life event covers a distance of 5k and Cancer Analysis UK is encouraging ladies of all ages and levels of fitness to participate. To sign up for a Race for Life event and for a lot more data on how to take part in the ‘Girls Just Want to Have Fun’ single, go to http://www.raceforlife.org

‘Girls Just Wish to Have Fun’, in aid of Cancer Investigation UK’s Race for Life, is released right now (26 April) and is available exclusively in over 800 Tesco stores and to download on iTunes. Tesco has been a proud partner of Race for Life since 2002 and during the past nine years over 152,000 female members of staff have taken part, raising over an incredible ????5.6 million to support Cancer Investigation UK.

Notes

About Sonique and her cancer experience:

Sonique (real name Sonia Clarke), aged 41, is really a British Singer and DJ who is at present getting treated for breast cancer.

Sonique was diagnosed much less than a year ago in Could 2009. Soon after a biopsy, it was revealed that the illness had spread towards the lymph nodes under her arms and she was rushed straight into hospital for an operation to eliminate both the lump and lymph nodes. A week later Sonique had another operation to eliminate further tissue, which was then followed by five months of intensive chemotherapy that finished two months ago in November.

Soon right after this, physicians recommended that Sonique went though her third operation to get rid of extra tissue as a preventative measure. January and February will see Sonique go via six weeks of preventative radiotherapy which will hopefully signify the end of her cancer journey.

‘Girls Just Wish to Have Fun’ contributors include:

-Sonique, 41, British DJ and singer
-Lucie Jones, 18, X Factor Finalist 2009
-Nicola Tappenden, 27, Model and Celebrity Big Brother contestant
-Jaime Jay, 27, British singer
-Carol Decker, 53, British Recording Artist (80′s band T’Pau)
-Kym Marsh, 34, Actress/singer
-Nina Wadia, 42, Eastenders actress
-Kelli Young, 29, Singer who discovered fame with pop band Liberty X
-Penny Smith, 52, TV presenter (GMTV)
-Danielle Lloyd, 27, British glamour model
-Lucy Benjamin, 40, Actress
-Su-Elise Nash, 29, British singer who located fame in girlband Mis-Teeq
-Cheeky Girls, aka, Gabriella and Monica Irimia, both 28, female duo
-Lisa Scott-Lee, 35, British recording artist
-Hollyoaks actresses Loui Bately, Georgie Porter, Nicole Barber-Lane, Melissa Walton, Dominique Jackson and Alice Barlow
-Deanne Berry, 29, Fitness Expert (GMTV)
-Hundreds of females in shopping centres across the UK

Source
Cancer Analysis UK

Healthcare Prof:

In a letter Friday to HHS Secretary Kathleen Sebelius, WellPoint CEO Angela Braly stated a Reuters article stating that the company targets ladies with breast cancer for policy cancellations is inaccurate, The Hill‘s “Blog Briefing Room” reports (Zimmerman, “Blog Briefing Room,” The Hill, 4/24).

The day before, Sebelius sent the company a letter stating that she was “surprised and disappointed to read media accounts indicating that WellPoint routinely rescinds wellness insurance coverage from females lately diagnosed with breast cancer.” The article also reported that WellPoint targeted pregnant ladies for rescissions. Sebelius urged WellPoint to end the practice, adding that such rescissions “will soon be illegal” under a provision within the federal wellness reform law (PL 111-148), which “specifically prohibits insurance companies from rescinding policies, except in cases of fraud or intentional misrepresentation of material fact” ( Women’s Wellness Policy Report, 4/23).

In her response to Sebelius, Braly stated she was “disappointed” to read Sebelius’ letter. She added, “To be absolutely clear, WellPoint does not single out females with breast cancer for rescission. Period” (“Blog Briefing Room,” The Hill, 4/24).

Braly also wrote, “Breast cancer is actually a devastating illness and ought to not be politicized.” She requested a meeting with Sebelius to discuss the matter.

A Thomson Reuters spokesperson stated Reuters stands by its story (Gershberg/Clark, Reuters, 4/23).

Reprinted with type permission from http://www.nationalpartnership.org. You’ll be able to view the whole Daily Women’s Well being Policy Report, search the archives, or sign up for e-mail delivery here. The Day-to-day Women’s Well being Policy Report can be a free of charge service of the National Partnership for Ladies & Families, published by The Advisory Board Company.

? 2010 The Advisory Board Company. All rights reserved.

For further details please see:
Reuters Reports WellPoint Targets Breast Cancer Patients, Pregnant Women For Rescissions

Healthcare Prof:

A new study finds that variables known to increase the danger of breast cancer among white girls have less influence in Hispanic girls. Published early on the web in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that investigation is essential to evaluate how breast cancer threat variables differ among ethnic and racial populations.

Breast cancer occurs much more regularly in particular ethnic and racial groups, but the factors behind these differences are not completely understood. To investigate the problem, Lisa Hines, ScD, of the University of Colorado at Colorado Springs led a study that regarded as how established breast cancer threat aspects – including reproductive history, family members history of breast cancer, menstrual history, hormone use, alcohol consumption, physical activity, height, and body mass index – might be involved in explaining several of the observed differences in the occurrence of breast cancer amongst racial and ethnic groups. They studied breast cancer amongst females from the Southwest United States who had been enrolled inside the population-based, case-control 4-Corners Breast Cancer Study, which was designed to investigate variables that contribute to the difference in breast cancer incidence rates observed in between Hispanic and non-Hispanic white ladies.

Prior studies have shown that non-Hispanic white women have a greater incidence of breast cancer than Hispanic ladies. In this existing study, the researchers found that 62 percent to 75 percent of breast cancer cases amongst non-Hispanic white women had been attributed to recognized breast cancer threat elements, compared with only 7 to 36 percent of cases amongst Hispanic females. Hispanic girls were much more likely to have characteristics related to lower breast cancer danger, for example earlier age at 1st childbirth, getting much more young children, shorter height, less hormone use, and much less alcohol consumption. Among premenopausal ladies, taller height and household history of breast cancer were related to elevated threat in non-Hispanic white ladies but were not amongst Hispanic ladies. Amongst postmenopausal girls, certain breast cancer risk aspects in non-Hispanic whites (such as recent hormone therapy use and younger age at menarche) had no or only weak associations with breast cancer in Hispanics.

These findings suggest that numerous of the danger elements studied to date explain fewer of the breast cancer instances that arise in Hispanic females compared with non-Hispanic white women. “These differences are most likely to contribute to disparities in breast cancer incidence rates, and could potentially reflect differences in breast cancer development among these ethnic groups,” said Dr. Hines. For example, ethnic differences in genetic and environmental or life-style aspects may have an effect on individuals’ susceptibility towards the development of breast cancer.

The authors noted that the study’s findings also indicate that the use of models to estimate a woman’s danger of breast cancer that were developed from studies amongst non-Hispanic white populations have to be evaluated among other ethnic and racial populations.

Article: “Comparative analysis of breast cancer risk elements among Hispanic and non-Hispanic white females.” Lisa M. Hines, Betsy Risendal, Martha L. Slattery, Kathy Baumgartner, Anna R. Giuliano, Carol Sweeney, Dana E. Rollison, and Tim Byers. Cancer; Published On the internet: April 26, 2010 (DOI: 10.1002/cncr.25154).

Source:
Claire Greenwell
American Cancer Society

four (4 votes)

Healthcare Prof:

5 (1 votes)

U.S. Department of Well being and Human Services (HHS) Secretary Kathleen Sebelius sent a letter to WellPoint urging them to quickly finish their practice of dropping health insurance coverage for females with breast cancer, soon after Reuters reported that the organization “has particularly targeted ladies with breast cancer for aggressive investigation using the intent to cancel their policies.”

The Affordable Care Act will ban such rescissions, except in situations of blatant misrepresentation or fraud, beginning this fall.

In her letter, Sebelius writes, “WellPoint should not wait to end the unconscionable practice of deliberately operating to deny health insurance coverage to ladies diagnosed with breast cancer. I urge you to right away cease these practices and abandon your efforts to rescind health insurance coverage from patients who need it most.”

The text of the letter is included beneath.

April 22, 2010

[To: Angela Braly, WellPoint]

Dear Ms. Braly:

I was surprised and disappointed to read media accounts indicating that WellPoint routinely rescinds well being insurance coverage from women lately diagnosed with breast cancer. Today’s report from Reuters indicating that your firm “has particularly targeted girls with breast cancer for aggressive investigation with the intent to cancel their policies” is disturbing, and this practice is deplorable.

As you know, the practice described in this article will soon be illegal. The Cost-effective Care Act particularly prohibits insurance organizations from rescinding policies, except in circumstances of fraud or intentional misrepresentation of material truth.

WellPoint ought to not wait to finish the unconscionable practice of deliberately working to deny well being insurance coverage to females diagnosed with breast cancer. I urge you to right away cease these practices and abandon your efforts to rescind health insurance coverage from patients who require it most.

Breast cancer is the second-leading type of cancer amongst women, has touched millions of families, and will impact one in eight American females during their lifetime. This year alone, an estimated 192,000 American females will likely be diagnosed with breast cancer.

I hope you’ll consider these females and their households as you work to finish this dangerous practice.

Sincerely,

Kathleen Sebelius

Source
HHS

5 (2 votes)

Healthcare Prof:

Preeclampsia is a high blood pressure syndrome in pregnant mothers that is brought on when the blood supply in the placenta of the creating baby is restricted. The blood-deprived placenta releases factors that cause the raise in blood pressure inside the mother. Doctors need to monitor these females closely and they could be forced to deliver the baby early to guard the mother and also the baby. Most women’s blood pressure returns to normal levels soon after they deliver the placenta.

A Risk With Benefits

Women that create preeclampsia paradoxically appear to have decreased incidence of developing breast cancer. But why this significant condition might have other beneficial effects is unknown.

Anne Gingery of the Department of Physiology and Pharmacology at the University of Minnesota Medical School, Duluth, MN, has investigated how specific variables released from the placenta of girls with preeclampsia inhibit the growth of breast cancer cells. Gingery is going to be presenting her most current findings in the 2010 Experimental Biology meeting in Anaheim, CA from April 24-28 (see here). Her presentation is entitled “Soluble Endoglin Inhibits Breast Cancer Cell Proliferation.”

Dr. Gingery’s investigation utilizes a rat model with preeclampsia, which they induce by restricting the blood flow towards the rat’s placenta with clips. The placenta has numerous blood vessels, so the variables released for the duration of preeclampsia finish up within the blood stream. The serum – what is left following the cells are filtered out of the blood – of these animals possesses anti-cancer properties. Gingery tested an array of breast cancer cells treated with the serum that resulted in decreased growth of cancer cells.

The Elements Involved

Gingery studies two aspects released during preeclampsia: sFlt-1 and soluble endoglin. sFlt-1 is a soluble version of a protein referred to as VEGF (vascular endothelial growth factor), which regulates the growth of cells. The other factor, soluble endoglin, is actually adecreasingimportant factor in breast cancer development and progression. According to Gingery, at the early stages of cancer this pathway frequently suppresses tumor growth, but in advanced cancer it can really promote cancer progression.

Things Are Complicated: The Elements Only Protect the Mothers

Gingery’s work expanded to look at the pups born from mother rats with preeclampsia. Surprisingly, the preliminary results reveal that the pups born from the mother’s with preeclampsia are more likely to create breast tumors. The group is examining the time it takes to create tumors along with the characteristics of the tumors. On-going study is evaluating whether or not the mothers using the preeclampsia will have a reduced incidence of breast tumors.

Gingery speculates that maybe the variables released throughout preeclampsia affect the stem cells of the mammary gland in some way that modifications how the cells develop, which may possibly impact protection against cancer. But she reiterates that this study is in its early stages and much is nonetheless unknown.

By studying the affects of preeclampsia on the protection against breast cancer, Gingery hopes to identify new targets that will be utilized in prevention and also the development of therapeutics. “Preeclampsia just isn’t a condition we want any mother to endure,” explains Gingery. “We are basically making use of a distinctive strategy to come across variables to be employed for care and therapy of cancer. Occasionally it just takes looking at a question differently.”

Note

The presentation is part of the Experimental Biology 2010 conference getting held April 24-28, 2010 at the Anaheim Convention Center.

Physiology could be the study of how molecules, cells, tissues and organs function to generate health or illness. The American Physiological Society has been an integral portion of the discovery procedure since it was established in 1887.

Source
Federation of American Societies for Experimental Biology (FASEB)

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Nowadays

Healthcare Prof:

Ten McGill University researchers received an important boost, by way of the announcement of $1.7 million in new funding awarded by way of the Canada Foundation for Innovation’s Leaders Opportunity Fund. “CFI investments are critical for our analysis leaders, to ensure that their analysis remains innovative and second to none,” said Dr. Rima Rozen, Interim Vice-Principal (Investigation and International Relations) at McGill.

The McGill projects range from important work in cancer investigation to the study of bone degeneration within the spine.

The funds are component of a total $27.9 million announced by the Canada Foundation for Innovation (CFI) to support 118 projects at 32 institutions across Canada. Of that amount, $21.4 million was awarded under the Leaders Chance Fund – a program developed to provide infrastructure and help Canadian institutions attract and retain leading researchers.

“We can say with conviction that Canada is becoming a place exactly where world-class researchers want to be,” stated Dr. Eliot Phillipson, President and CEO of the CFI, an independent corporation created by the Government of Canada to fund investigation infrastructure at Canadian universities, colleges, research hospitals and non-profit research institutions. “This CFI investment will further create Canada’s global reputation as a place exactly where outstanding analysis and coaching is becoming conducted.”

The McGill investigation projects are: Dr. Petra Rohrbach
Dissecting Development and Drug Resistance Mechanisms in Plasmodium Falciparum Utilizing Live Cell Imaging Techniques
$221,873

Dr. Yojiro Yamanaka
Epithelial Morphogenesis in Early Development and Cancer
$120,000

Dr. Danielle Malo
Functional and Comparative Genomics of the Interaction of the Host with Salmonella
$270,941

Dr. Lisbet Haglund
Identification, Generation and Repair of Intervertebral Disc Degeneration
$100,000

Dr. Eric Galbraith
Integrated Earth Program Dynamics Laboratory
$103,600

Dr. Aaron Sprecher
Laboratory for Integrated Prototyping and Hybrid Environments (LIPHE)
$362,562

Dr. Koren Mann
Mechanisms of Metal-Induced Toxicity
$100,000

Dr. Nancy Braverman
Molecular and Therapeutic Studies in Peroxisome Biogenesis Disorders
$140,000

Dr. Josie Ursini-Siegel
Role of ShcA in the Establishment of a Productive Tumor Microenvironment that Facilitates Breast Cancer Progression
$120,000

Dr. Dao Nguyen
The Study of Pseudomonas Aeruginosa Biofilm and Antibiotic Tolerance
$140,000 Source:
William Raillant-Clark
McGill University

Healthcare Prof:

It is an accepted truth that genetics play a important role in a person’s susceptibility to cancer, and that all through life, mutations can cause damage to tumor suppressor genes (TSGs) further increasing the probabilities of developing cancerous tumors.

Now a brand new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) demonstrates that even subtle changes in expression of the PTEN tumor suppressor gene can substantially boost cancer susceptibility in distinct tissues, suggesting that environmental variables, for example diet plan or exposure to carcinogens, may have a much more dramatic influence on tumor development than previously recognized. Appearing in this week’s Advance On-line issue of Nature Genetics, the findings propose a new model for the role of tumor suppressor genes in the onset of cancer and could prove useful inside the development of diagnostic tests targeted to these gene alterations.

“More than 30 years ago, it was proposed that a person’s susceptibility to cancer was dependent on a ‘two-hit’ model,” explains Pier Paolo Pandolfi, MD, PhD, Director of the Cancer Genetics Plan at BIDMC and George C. Reisman Professor of Medicine at Harvard Medical School. This meant that there had to be two genetic alterations of a single tumor suppressor gene (TSG) to activate tumor development – one gene could be missing from birth, even though the second would be lost to other aspects in the course of one’s lifetime.

“Our study adds yet another dimension to this Knudsonian model [so-named for its creator, cancer geneticist Alfred Knudson] demonstrating that cancer susceptibility can be driven in certain tissues by a progressive – but slight – continuum reduction in tumor suppressor levels,” explains Pandolfi. “Consequently, subtle modulation of TSG levels can lead to increased cancer susceptibility. This implies that any factor that affects PTEN levels – chemicals, diet program, other carcinogens – could enhance tumor susceptibility, even inside the absence of a full blown genetic mutation.”

Tumor suppressor genes function to slow down cell division, repair DNA and aid alert damaged cells when it truly is time to die, and PTEN is one such example. (Furthermore to stopping uncontrolled cell growth, PTEN is also responsible for controlling cell movement or migration, controlling the adhesion of cells to surrounding tissues and helping to manage the formation of new blood cells.) But, when TSGs are absent or malfunctioning – as may be the case of a genetic mutation – cells can multiply too speedily, growing out of control and leading towards the development of cancerous tumors.

In recent years, with the advent of functional genomics, the thought that subtle modifications in TSG levels could influence tumor development had been proposed but not formally investigated. To test this hypothesis, the Pandolfi team created a mouse model of PTEN that expressed the gene at approximately 80 percent of total levels. Next, they utilised a gene targeting method which drives a transcriptional interference of the PTEN gene, resulting in inefficient protein production. The authors report that the presence of 1 targeted allele resulted in roughly 80 percent of PTEN expression relative towards the regular degree of PTEN expressed in distinct tissues – in this case, mammary gland tissue. And, as predicted, the scientists subsequently identified an elevated incidence of mammary tumors in these mice, and through a careful histopathological and molecular analysis were in a position to demonstrate that mammary tumors maintained each the targeted and wild-type PTEN alleles intact.

“These mice showed mammary cancer at a high incidence and inside the absence of further alterations to the PTEN gene,” explains Pandolfi. “This confirms that the PTEN gene is actually a ‘quasi-insufficient’ tumor suppressor, such that even a subtle 20 percent decrease in gene expression is adequate to impair its full tumor-suppressive activity.”

This discovery, say the authors, is tremendously relevant for how genetic alterations in cancer are detected, studied, evaluated and treated. “From a diagnostic perspective, our findings encourage the implementation of quantitative techniques to evaluate cancer gene expression levels, and also the design of therapies oriented to target these alterations,” they write. Adds Pandolfi, “Our instant aim is usually to develop a genetic test to be utilized for the screening of patients at risk of developing breast cancer. Such a test may well also be useful in predicting the outcome of certain treatments [i.e. Trastuzumab] for breast cancer patients.”

Coauthors incorporate BIDMC investigators Andrea Alimonti, Arkaitz Carracedo and John Clohessy, Caterina Nardella, Ainara Egia, Leonardo Salmena, Katia Sampieri and William J. Haveman; Edi Brogi of Memorial Sloan-Kettering Cancer Center; Andrea Richardson of Brigham and Women’s Hospital; Jiangwen Zhang of Harvard University; and Lloyd Trotman of Cold Spring Harbor Laboratory.

This study was supported, in portion, by grants from the National Cancer Institute and support from the European Molecular Biology Organization.

Source:
Bonnie Prescott
Beth Israel Deaconess Medical Center